Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma

OncoImmunology

Volumn 3, Issue 5, 2014, Pages

  Wainwright, Derek A ^a   Lesniak, Maciej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Glioblastoma; Immunosuppression; Immunotherapy; Metabolism; Tryptophan

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; PROGRAMMED DEATH 1 LIGAND 1; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; GLIOBLASTOMA; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INTRACRANIAL DRUG ADMINISTRATION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOPENIA; NONHUMAN; OVERALL SURVIVAL; REGULATORY T LYMPHOCYTE; RISK REDUCTION; SUPPRESSOR CELL; TUMOR MICROENVIRONMENT;

EID: 84904045062     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.28927     Document Type: Article

References (9)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 2005; 352:987-96; PMID:15758009; http://dx.doi.org/10.1056/NEJMoa043330.
2. Didenko VV, Ngo HN, Minchew C, Baskin DS. Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism. J Neurosurg, 2002; 96:580-4; PMID:11883844; http://dx.doi.org/10.3171/jns.2002.96.3.0580.
3. El Andaloussi A, Lesniak MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol, 2006; 8:234-43; PMID:16723631; http://dx.doi.org/10.1215/15228517-2006-006.
4. Fecci PE, Sweeney AE, Grossi PM, Nair SK, Learn CA, Mitchell DA, Cui X, Cummings TJ, Bigner DD, Gilboa E, et al. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res, 2006; 12:4294-305; PMID:16857805; http://dx.doi.org/10.1158/1078-0432.CCR-06-0053.
5. El Andaloussi A, Han Y, Lesniak MS. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg, 2006; 105:430-7; PMID:16961139; http://dx.doi.org/10.3171/jns.2006.105.3.430.
6. Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim C, Tobias AL, Cheng Y, Kim J, Zhang L, Qiao J, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4 and PD-L1 in mice with brain tumors. Clin Cancer Res 2014;In press; PMID:24691018; http://dx.doi.org/10.1158/1078-0432.CCR-14-0514
7. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med, 2013; 369:122-33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369.
8. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med, 2014; 6:26ra32; PMID:24598590; http://dx.doi.org/10.1126/scitranslmed.3008095.
9. Mortenson ED, Park S, Jiang Z, Wang S, Fu YX. Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells. Clin Cancer Res, 2013; 19:1476-86; PMID:23363817; http://dx.doi.org/10.1158/1078-0432.CCR-12-2522.